Clinical Trial Update: IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigates IBI363 plus bevacizumab with or without nab-paclitaxel as second-line treatment for advanced gastric cancer, sponsored b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• IBI363
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Advan'ce'd, Advanced | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING